Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK, and when can generic versions of MERCK drugs launch?
MERCK has ninety-two approved drugs.
There are twenty-six US patents protecting MERCK drugs.
There are seven hundred and thirty-five patent family members on MERCK drugs in sixty-three countries and one hundred and seventy-eight supplementary protection certificates in nineteen countries.
Summary for Merck
| International Patents: | 735 |
| US Patents: | 26 |
| Tradenames: | 77 |
| Ingredients: | 70 |
| NDAs: | 92 |
| Patent Litigation for Merck: | See patent lawsuits for Merck |
| PTAB Cases with Merck as patent owner: | See PTAB cases with Merck as patent owner |
Drugs and US Patents for Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | AP | RX | Yes | Yes | 9,358,297 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-002 | Aug 13, 2014 | RX | Yes | No | 7,951,797 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Merck Kgaa | LEVOTHYROXINE SODIUM | levothyroxine sodium | TABLET;ORAL | 076752-005 | Jun 16, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Merck | PRIMAXIN | cilastatin sodium; imipenem | INJECTABLE;INJECTION | 062756-001 | Jan 8, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Merck | DECADERM | dexamethasone | GEL;TOPICAL | 013538-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Merck | DOLOBID | diflunisal | TABLET;ORAL | 018445-001 | Apr 19, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Merck | DIUPRES-250 | chlorothiazide; reserpine | TABLET;ORAL | 011635-003 | Aug 26, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-003 | Jun 30, 2006 | 6,096,742 | ⤷ Try a Trial |
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-001 | May 28, 1998 | 4,283,408*PED | ⤷ Try a Trial |
| Merck Sharp Dohme | DUTREBIS | lamivudine; raltegravir potassium | TABLET;ORAL | 206510-001 | Feb 6, 2015 | 7,820,660 | ⤷ Try a Trial |
| Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-001 | Jun 3, 1998 | 6,337,090*PED | ⤷ Try a Trial |
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-002 | Mar 26, 2003 | 5,145,684 | ⤷ Try a Trial |
| Merck | DOLOBID | diflunisal | TABLET;ORAL | 018445-001 | Apr 19, 1982 | 3,714,226 | ⤷ Try a Trial |
| Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-001 | Oct 16, 2006 | 6,890,898 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
| ➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
| ➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
| ➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
| ➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
| ➤ Subscribe | Oral Solution | 70 mg/75 mL | ➤ Subscribe | 2007-09-07 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
| ➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
| ➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
| ➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
| ➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
| ➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
| ➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
| ➤ Subscribe | For Injection | 50 mg/vial and 70 mg/vial | ➤ Subscribe | 2009-06-26 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
International Patents for Merck Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2004504404 | ⤷ Try a Trial |
| Hungary | E052080 | ⤷ Try a Trial |
| Eurasian Patent Organization | 007060 | ⤷ Try a Trial |
| Israel | 162296 | ⤷ Try a Trial |
| Guatemala | 201200313 | ⤷ Try a Trial |
| New Zealand | 603800 | ⤷ Try a Trial |
| Slovakia | 752003 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2666774 | CA 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 1385870 | C 2011 014 | Romania | ⤷ Try a Trial | PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718 |
| 1412357 | DO 77; 5006-2008 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 |
| 0443983 | C00443983/03 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| 0509752 | 49/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306 |
| 0509752 | SPC/GB99/043 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
